Worldwide, Primary hyperoxaluria prevalence is estimated to range from 1 to 3 per million population. In the 7MM, the total Primary hyperoxaluria prevalent population was found to be 11,918 in 2020, which is expected to further increase by 2030. As per DelveInsight, the Primary Hyperoxaluria market is expected to soar at a CAGR of 40.40% during the study period 2018-30 in the 7MM.
The promising clinical research and development activities by key companies in the domain such as OxThera, Dicerna Pharmaceuticals, Allena Pharmaceuticals, BIOCODEX, and others will be the dominant factor for the Primary Hyperoxaluria market growth and also in bridging the treatment gap. Additionally, the Primary Hyperoxaluria therapeutic diagnostics modalities and a better understanding of the disease will also boost the market growth.
For more details, visit: Primary Hyperoxaluria Market Clinical Therapies